Muscle loss biotech Atara Biotherapeutics sets terms for $75 million IPO

By
A A A

Atara Biotherapeutics, an early-stage biotech targeting muscle loss in patients with end-stage renal disease, announced terms for its IPO on Thursday. The Brisbane, CA-based company plans to raise $75 million by offering 5.0 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Atara would command a fully diluted market value of $305 million.

Atara Biotherapeutics, which was founded in 2012, plans to list on the NASDAQ under the symbol ATRA. Atara initially filed confidentially on April 10, 2014. Goldman Sachs and Citi are the joint bookrunners on the deal. It is expected to price during the week of July 21, 2014.




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.




This article appears in: News Headlines , IPOs

Referenced Stocks: ATRA

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Most Unique Homes for Sale
Most Unique Homes for Sale          

Stocks

Referenced

Most Active by Volume

76,389,843
  • $16.11 ▲ 1.13%
54,914,450
  • $128.95 ▲ 3.04%
49,328,034
  • $14.15 ▲ 5.44%
37,951,947
  • $16.54 ▲ 4.88%
36,958,408
  • $37.84 ▼ 2.87%
35,690,832
  • $48.655 ▲ 0.03%
35,241,746
  • $6.50 ▼ 1.22%
34,734,899
  • $8.07 ▲ 5.08%
As of 5/1/2015, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com